NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the January 2012 NCCN Trends™ Survey, which focused on Breast Cancer. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS

Distribution of Respondent Types (n = 1,744)†

- Physician/Surgeon/Oncologist: 71%
- Nurse/Oncology Nurse or Clinical Nurse Specialist: 12%
- Pharmacist: 5%
- Physician Assistant or Nurse Practitioner: 5%
- Other Clinician: 8%

†Note: Percentages may not total 100 because of rounding.
Q1. Do you treat patients with breast cancer? (n=1,754)

- Yes: 76%
- No: 24%

Q2. Which assay do you use most frequently in your practice for assessing the risk of breast cancer recurrence? (n = 1,195)

- Clarient Insight® Dx Mammostrat® (molecular-based 5 antibody assay): 45%
- Mammaprint® (PCR-based 70 gene assay): 31%
- Oncotype DX® (PCR-based 21 gene assay): 17%
- Other: 3%
- None: 4%
Q3. Would having the results of an assay that determines the risk of breast cancer recurrence within 48 hours reduce anxiety for your patients? (n=1,127)

Results: January 2012

- Yes: 73%
- No: 27%
Q4. Are you aware of the inherent heterogeneity issues in breast cancer and how some PCR (polymerase chain reaction)-based assays that determine the risk of breast cancer recurrence may be confounded by proliferative stromal tissue, inflammatory cells, or benign tissue? (n=1,117)

Results: January 2012

BREAST CANCER

- Yes: 63%
- No: 37%
Q5. What is your level of interest in the following to learn more about assays used to determine the risk of breast cancer recurrence? (Check all that apply)†

- High Interest
- Moderate Interest
- Low Interest
- Not Interested

Results: January 2012

BREASt CAnCER

†Note: Percentages may not total 100 because of rounding
**NCCN Trends™** is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an NCCN Trends™ survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN  
Director, Business Insights  
215.690.0557  
maccracken@nccn.org

**National Comprehensive Cancer Network® (NCCN®)**

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

---

All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.